Rheumatoid Arthritis: key endpoint results by drug

The key endpoints of Rheumatoid Arthritis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Rheumatoid Arthritis page.

ACR20

ACR20 in Rheumatoid Arthritis: 28 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept67.9%39.7%+28.2wk 24.14 · n 424NCT00048568 Phase 3, primary
Acellbia65.7%a29.4%+36.3wk 24NCT02744196 Phase 3, primary
adalimumab63.3%29.5%+33.840 mg every other week · wk 24 · n 207NCT00195702 Phase 3, primary
adalimumab-aaty (Yuflyma)82.7%82.7% (Humira)—wk 24 · n 324NCT03789292 Phase 3, primary
adalimumab-afzb (Abrilada)68.3%71.3% (Adalimumab-EU)—wk 12 · n 297NCT02480153 Phase 3, primary
adalimumab-atto (Amjevita)74.6%72.4% (Adalimumab)—wk 24 · n 260NCT01970475 Phase 3, primary
baricitinib61.7%39.5%+22.24 mg · wk 12 · n 227NCT01721057 Phase 3, primary
BAT180669.9%a67.9% (reference tocilizumab)—wk 24NCT03830203 Phase 3, primary
brodalumab46%42.9%+3.1210 mg · wk 12 · n 63NCT00950989 Phase 2, secondary
certolizumab pegol54.8%23.9%+30.9wk 24 · n 312NCT02151851 Phase 3, primary
etanercept77.5%56.3% (Methotrexate)—25 mg · wk 24 · n 182NCT00445770 Phase 3, secondary
filgotinib76.6%49.9%+26.7200 mg · wk 12 · n 475NCT02889796 Phase 3, primary
golimumab44.4%33.1%+11.3100 mg + placebo · wk 14 · n 133NCT00264550 Phase 3, primary
HLX0160.7%a35.9%+24.8wk 24NCT03522415 Phase 3, primary
infliximab56.6%53% (Remicade-US)—wk 22 · n 228NCT02990806 Phase 3, primary
infliximab-dyyb (Inflectra)60.9%a58.6% (innovator infliximab (INX))—wk 30NCT01217086 Phase 3, primary
infliximab-qbtx (Ixifi)61.1%63.5% (Infliximab-EU Remicade (INX))—wk 14 · n 324NCT02222493 Phase 3, primary
ixekizumab39%23.4%+15.6180 mg · wk 12 · n 59NCT00966875 Phase 2, secondary
Levilimab68.6%a38.5%+30.1wk 12NCT04227366 Phase 3, primary
Methotrexate83.2%50% (DMARD + Methotrexate)—wk 24 · n 279NCT00848354 Phase 4, secondary
obefazimod15.8%20%−4.2100 mg · wk 12 · n 19NCT03813199 Phase 2, secondary
PF-0528058677.1%90% (Rituximab-EU)—wk 25 · n 58NCT01643928 Phase na, primary
Piclidenoson42.9%21.6%+21.31 mg · wk 12 · n 42NCT01034306 Phase 2, primary
Rituximab50.6%23.3%+27.32 x 1.0 g · wk 24 · n 170NCT00299130 Phase 3, primary
Sarilumab66.4%33.4%+33200 mg q2w · wk 24 · n 399NCT01061736 Phase 2/3, primary
tocilizumab60.9%31.5%+29.4162 mg sc · wk 24 · n 437NCT01232569 Phase 3, primary
tofacitinib52.7%31.2%+21.55 mg · wk 24 · n 311NCT00856544 Phase 3, primary
upadacitinib63.8%35.7%+28.115 mg · wk 12 · n 221NCT02675426 Phase 3, primary

Drugs checked with no result here: 50 not reported, 6 not posted, 2 trial running.

ACR50

ACR50 in Rheumatoid Arthritis: 19 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept39.9%16.8%+23.1wk 24.14 · n 424NCT00048568 Phase 3, secondary
adalimumab41.2%45.9% (Methotrexate)—wk 52 · n 274NCT00195663 Phase 3, primary
adalimumab-afzb (Abrilada)59.6%54.7% (Adalimumab-EU)—wk 26 · n 297NCT02480153 Phase 3, secondary
adalimumab-atto (Amjevita)49.2%52% (Adalimumab)—wk 24 · n 244NCT01970475 Phase 3, secondary
baricitinib44.1%21.5%+22.64 mg · wk 24 · n 227NCT01721057 Phase 3, secondary
brodalumab9.5%12.7%−3.2210 mg · wk 12 · n 63NCT00950989 Phase 2, primary
certolizumab pegol36.5%7.1%+29.4wk 24 · n 312NCT02151851 Phase 3, secondary
etanercept54.4%32.4% (Methotrexate)—25 mg · wk 24 · n 182NCT00445770 Phase 3, secondary
filgotinib57.9%33.3%+24.6200 mg · wk 24 · n 475NCT02889796 Phase 3, secondary
golimumab32.7%29.4%+3.3100 mg + placebo · wk 24 · n 159NCT00264537 Phase 3, primary
infliximab27.8%25.6% (Remicade-US)—wk 22 · n 227NCT02990806 Phase 3, secondary
Methotrexate62.0%23.2% (DMARD + Methotrexate)—wk 24 · n 279NCT00848354 Phase 4, primary
PF-0528058651.4%30% (Rituximab-EU)—wk 25 · n 58NCT01643928 Phase na, primary
Piclidenoson18.9%9.4%+9.51 mg · wk 12 · n 37NCT01034306 Phase 2, secondary
Rituximab25.9%9.3%+16.62 x 1.0 g · wk 24 · n 170NCT00299130 Phase 3, secondary
Sarilumab40.8%18.2%+22.6200 mg q2w · wk 24 · n 184NCT01709578 Phase 3, secondary
tocilizumab32.2%9.7%+22.58 mg/kg · wk 24 · n 398NCT00106535 Phase 3, secondary
tofacitinib33.8%12.7%+215 mg · wk 26 · n 311NCT00856544 Phase 3, secondary
upadacitinib52.1%28.3% (Methotrexate)—15 mg · wk 12 · n 317NCT02706873 Phase 3, primary

Drugs checked with no result here: 54 not reported, 11 not posted, 2 trial running.

ACR70

ACR70 in Rheumatoid Arthritis: 19 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept19.8%6.5%+13.3wk 24.14 · n 424NCT00048568 Phase 3, secondary
adalimumab47.4%22.7%+24.7wk 26 · n 171NCT00870467 Phase 3, secondary
adalimumab-afzb (Abrilada)29.6%31% (Adalimumab-EU)—wk 26 · n 297NCT02480153 Phase 3, secondary
adalimumab-atto (Amjevita)26%22.9% (Adalimumab)—wk 24 · n 246NCT01970475 Phase 3, secondary
baricitinib24.2%7.9%+16.34 mg · wk 24 · n 227NCT01721057 Phase 3, secondary
brodalumab0%3.2%−3.2210 mg · wk 12 · n 63NCT00950989 Phase 2, secondary
certolizumab pegol16.7%2.7%+14wk 24 · n 312NCT02151851 Phase 3, secondary
etanercept25.8%11.9% (Methotrexate)—25 mg · wk 24 · n 182NCT00445770 Phase 3, secondary
filgotinib36.2%14.9%+21.3200 mg · wk 24 · n 475NCT02889796 Phase 3, secondary
golimumab16.1%25.9% (Golimumab)—100 mg · wk 24.14 · n 70NCT01715896 Phase 2, primary
infliximab10.6%12.1% (Remicade-US)—wk 22 · n 227NCT02990806 Phase 3, secondary
Methotrexate34.8%11.3% (DMARD + Methotrexate)—wk 24 · n 279NCT00848354 Phase 4, secondary
PF-0528058622.9%10% (Rituximab-EU)—wk 25 · n 58NCT01643928 Phase na, primary
Piclidenoson10.8%3.1%+7.71 mg · wk 12 · n 37NCT01034306 Phase 2, secondary
Rituximab10%5.2%+4.82 x 1.0 g · wk 24 · n 170NCT00299130 Phase 3, secondary
Sarilumab16.3%7.2%+9.1200 mg q2w · wk 24 · n 184NCT01709578 Phase 3, secondary
tocilizumab12.6%2%+10.68 mg/kg · wk 24 · n 398NCT00106535 Phase 3, secondary
tofacitinib25.4%12.1% (MTX)—5 mg BID · wk 24 · n 366NCT01039688 Phase 3, primary
upadacitinib20.8%5.9%+14.915 mg · wk 12 · n 221NCT02675426 Phase 3, secondary

Drugs checked with no result here: 54 not reported, 11 not posted, 2 trial running.

DAS28-CRP remission

DAS28-CRP remission in Rheumatoid Arthritis: 9 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept41.4%23.3%+18.1wk 52 · n 256NCT00122382 Phase 3, primary
adalimumab35.9%11.4% (Standard of Care)—wk 26 · n 39NCT01162421 Phase 4, secondary
certolizumab pegol16%5.7%+10.3wk 12 · n 851NCT00717236 Phase 3, secondary
etanercept58.2%43.6% (Standard COBRA-Slim Induction)—wk 28 · n 55NCT03649061 Phase 4, secondary
filgotinib48.4%16.2%+32.2200 mg · wk 24 · n 475NCT02889796 Phase 3, secondary
PF-0528058645.7%20% (Rituximab-EU)—wk 25 · n 58NCT01643928 Phase na, primary
Sarilumab28.8%7.2%+21.6200 mg q2w · wk 24 · n 184NCT01709578 Phase 3, secondary
tofacitinib23.0%5.2%+17.85 mg · wk 26 · n 309NCT00847613 Phase 3, secondary
upadacitinib48.3%18.5% (Methotrexate)—15 mg · wk 24 · n 317NCT02706873 Phase 3, primary

Drugs checked with no result here: 58 not reported, 15 not posted, 4 trial running.

HAQ-DI, change

HAQ-DI, change in Rheumatoid Arthritis: 18 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept-0.7-0.7 (Abatacept)—125 mg SC · wk 76 · n 52NCT01001832 Phase 2/3, primary
adalimumab-0.6-0.3−0.340 mg every other week · wk 52 · n 204NCT00195702 Phase 3, primary
adalimumab-afzb (Abrilada)-0.7-0.7 (Adalimumab-EU)—wk 26 · n 297NCT02480153 Phase 3, secondary
baricitinib-0.5-0.3−0.24 mg · wk 12 · n 227NCT01721057 Phase 3, secondary
certolizumab pegol-0.5-0.2−0.3wk 24 · n 306NCT02151851 Phase 3, secondary
etanercept-0.6-0.3 (Methotrexate)—25 mg · wk 24 · n 182NCT00445770 Phase 3, secondary
filgotinib-0.8-0.6−0.2200 mg · wk 24 · n 475NCT02889796 Phase 3, secondary
golimumab0.10.1±0100 mg + placebo · wk 24 · n 133NCT00264550 Phase 3, primary
infliximab-0.3-0.4 (Remicade-US)—wk 22 · n 227NCT02990806 Phase 3, secondary
ixekizumab-0.5-0.2−0.3180 mg · wk 12 · n 37NCT00966875 Phase 2, secondary
Methotrexate-0.8-0.5 (DMARD + Methotrexate)—wk 24 · n 279NCT00848354 Phase 4, secondary
obefazimod-0.1-0.2+0.1100 mg · wk 12 · n 19NCT03813199 Phase 2, secondary
PF-05280586-0.4-0.5 (Rituximab)—wk 25 · n 73NCT01526057 Phase 2, secondary
Rituximab-1.0-0.8−0.21.0 g x 2 · wk 52 · n 249NCT00299104 Phase 3, secondary
Sarilumab-0.5-0.3−0.2200 mg q2w · wk 12 · n 171NCT01709578 Phase 3, primary
tocilizumab-0.5-0.3−0.2162 mg sc · wk 24 · n 348NCT01232569 Phase 3, secondary
tofacitinib-0.5-0.2−0.35 mg · wk 13 · n 240NCT00814307 Phase 3, primary
upadacitinib-0.6-0.3−0.315 mg · wk 12 · n 216NCT02675426 Phase 3, secondary

Drugs checked with no result here: 55 not reported, 11 not posted, 2 trial running.

Modified Sharp score, change

Modified Sharp score, change in Rheumatoid Arthritis: 13 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Abatacept0.52.5−2wk 52 · n 401NCT02504268 Phase 3, secondary
adalimumab0.12.7−2.640 mg every other week · wk 52 · n 183NCT00195702 Phase 3, primary
baricitinib0.30.8−0.5wk 24 · n 470NCT01710358 Phase 3, secondary
certolizumab pegol0.41.6−1.2wk 52 · n 158NCT01451203 Phase 3, primary
Denosumab (Prolia)00±0180 mg · wk 24 · n 69NCT00095498 Phase 2, secondary
etanercept3.39.8 (Methotrexate)—25 mg · wk 52 · n 181NCT00445770 Phase 3, primary
filgotinib0.10.4−0.2200 mg · wk 24 · n 467NCT02889796 Phase 3, secondary
golimumab1.31.4−0.1100 mg + placebo · wk 52 · n 159NCT00264537 Phase 3, primary
Methotrexate0.41.4 (DMARD + Methotrexate)—wk 24 · n 247NCT00848354 Phase 4, secondary
Rituximab0.41.1−0.71.0 g x 2 · wk 52 · n 244NCT00299104 Phase 3, primary
tocilizumab0.31.1−0.88 mg/kg · wk 52 · n 348NCT00106535 Phase 3, primary
tofacitinib0.10.5−0.35 mg · wk 26 · n 286NCT00847613 Phase 3, primary
upadacitinib0.10.7 (Methotrexate)—15 mg · wk 24 · n 279NCT02706873 Phase 3, primary

Drugs checked with no result here: 58 not reported, 12 not posted, 3 trial running.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 86 approved or late-stage drugs with a featured trial in Rheumatoid Arthritis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.